AbbVie seeks EMA approval for Skyrizi subcutaneous use in Crohn's

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. NVDA
3. USO
4. SPY
5. SRRK
6. DFTX
7. AZN
8. CGEM
9. SATL
10. LYNX

Go back to AbbVie seeks EMA approval for Skyrizi subcutaneous use in Crohn's
AbbVie (NYSE: ABBV) Delayed: 261.70 +4.58 (1.78%)
Previous Close $257.12    52 Week High $68.12 
Open $261.67    52 Week Low $50.71 
Day High $264.65    P/E 56.77 
Day Low $260.10    EPS $4.61 
Volume 1,569,927